Scotiabank Lifts Amgen Target Price to $500
Scotiabank analyst Louise Chen has maintained a buy rating for Amgen (AMGN.US), raising the target price from $450 to $500.
According to TipRanks data, Chen's recommendations have a success rate of 54.1% and an average return of 7.2% over the past year.